Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Hopes To Balance Upfront Time Investment With Easier Reviews In New PMA Program

This article was originally published in The Gray Sheet

Executive Summary

CDRH Director Jeffrey Shuren hopes that the early, concentrated collaboration that his staff will engage in with manufacturers for select “Expedited Access PMA” devices will make the reviews themselves substantially quicker and easier, he said in an interview.

You may also be interested in...



CDRH's Expedited Access Pathway: 17 Devices And Counting

A system using nerve stimulation to treat diaphragm atrophy in mechanical ventilation patients is the latest product to be granted EAP designation. FDA officials recently confirmed that 17 devices have been accepted to the expedited development pathway about a year after the program launched.

FDA’s Expedited PMA Pathway Proposal: To Expand Or Contain?

Companies want FDA to expand the bounds of its accelerated device development program, while others urge FDA to be cautious.

Leap Ahead With EAP? FDA Proposes New Expedited PMA Pathway

The newly proposed “expedited access” PMA program combines early and outsized interactions between reviewers and manufacturers with the promise of lightened premarket requirements for selected products – if the potential payoff to patients is large enough and postmarket controls are sufficient.

Related Content

Topics

UsernamePublicRestriction

Register

MT032930

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel